Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna's (MRNA) bivalent COVID-19 booster vaccine, mRNA-1273.222, is designed to target the Omicron BA.4 and BA.5 subvariants. The vaccine has been developed specifically for the U.S. market.

Moderna (MRNA) Seeks FDA Nod for Omicron-Based COVID Jab

Carnival

Match Group

Investors have pulled back from the stock market in the wake of downbeat economic data, as they wait for commentary from the Federal Reserve on Friday.

The S&P 500 Has Pulled Back From Its August Peak. Moderna, Carnival, and Match Are Part of the Blame.

BioNTech SE

Pfizer

Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor Day, according to a new report.

Omicron-targeting COVID boosters may be out after Labor Day, and Moderna has joined Pfizer and BioNTech in filing for authorization

Alcoa

Applied Materials

Lam Research

Micron Technology

Charles Schwab

Skechers U.S.A.

Sony

Wells Fargo

Patrick Degorce is the founder and chief executive officer (CEO) of Theleme Partners.

These Are The Top 10 Holdings Of Patrick Degorce

Moderna Inc. MRNA, +0.92% said late Tuesday it has completed its submission to the U.S. Food and Drug Administration for the emergency-use authorization for its experimental bivalent COVID-19 booster for those who are 18 years old or older. The new shot targets the original strain of the virus as well as the BA.4 and BA.5 strains, thought to be the prevalent ones in the U.S. and other countries.

Moderna completes FDA submission for new COVID-19 booster

Moderna stock inched higher late Tuesday just before announcing it asked the FDA to sign off on its updated Covid booster shot. The post Moderna Asks FDA To Sign Off On Its Updated Covid Booster Shot appeared first on Investor's Business Daily.

Moderna Asks FDA To Sign Off On Its Updated Covid Booster Shot

mRNA-1273.222 Targets BA.4/BA.5 Strains of Omicron Variant Pending Authorization, Moderna Ready to Ship Bivalent Booster mRNA-1273.222 in September Clinical Data Available for Moderna's Bivalent COVID-19 Booster Vaccines Have Met All Primary Endpoints and Support Request for Emergency Use Authorization CAMBRIDGE, MA / ACCESSWIRE / August 23, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has completed its submission to the U.S. Food and Drug Administration (FDA) for emergency use authorization for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222. The application is for a 50 µg booster dose for adults 18 years of age and older, and is based on preclinical data as well as clinical trial data available for the company's BA.1 Omicron-targeting bivalent booster candidate, mRNA-1273.214.

Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222

Moderna's (MRNA) Omicron-specific bivalent vaccine booster is yet to be approved by Canadian health authorities. The government seeks to purchase 12 million doses of the same in 2022.

Moderna (MRNA) to Supply Omicron-based COVID Jab in Canada

Moderna Inc. MRNA, -2.60% said Monday it will supply the Canadian government with 12 million doses of its bivalent COVID vaccine that targets the original virus and the omicron variant. The government has exercised an option to purchase 4.5 million doses and moved ahead with the scheduled delivery of 1.5 million doses from 2023 to 2022.

Moderna to supply Canadian government with 12 million doses of its bivalent COVID vaccine

Government of Canada exercises option to purchase an additional 4.5 million doses of Moderna's Omicron-containing bivalent vaccine booster candidates CAMBRIDGE, MA / ACCESSWIRE / August 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Government of Canada has exercised its option to purchase an additional 4.5 million doses of an Omicron-containing bivalent vaccine booster candidate from the Company, in addition to moving forward the scheduled delivery of 1.5 million doses of the bivalent vaccine candidate from 2023 to 2022. Moderna and the Government of Canada have also agreed to convert six million doses of the Company's COVID-19 vaccine (Spikevax, mRNA-1273) to an Omicron-containing bivalent vaccine.

Moderna to Supply 12 Million Doses of Omicron-Containing Bivalent COVID-19 Booster Vaccines to the Government of Canada

Exact Sciences

Mind Medicine MindMed

Expectations for these stocks are still sky high.

3 Growth Stocks That Could Soar 51% to 385%, According to Wall Street

SIGA Technologies

Shares of the company have jumped more than 60% in just the past month.

Could SIGA Technologies Become the Next Moderna?

AstraZeneca

Johnson & Johnson

Here is a rundown of the top pharmaceutical stocks to know about, ranked by market capitalization: Johnson & Johnson, Pfizer, Eli Lilly, AbbVie

Ups & Downs: Top Pharmaceutical Stocks Post-COVID

Analysts still have great expectations for these beaten-down stocks.

3 Growth Stocks That Could Soar 35% to 84%, According to Wall Street

Investors are worried that big change in public policy might have an outsize impact on the company.

Why Moderna Was Sinking This Week

Novavax

The Biden administration is planning to stop paying for Covid vaccines and treatments, a move that could buoy some Covid stocks. The post Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions appeared first on Investor's Business Daily.

Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions

Advanced Micro Devices

Blackstone Group

Cigna

ServiceNow

NVIDIA

Tesla

Uber

Vertex Pharmaceuticals

Sales growth is a very important financial metric that investors consider before making a buy decision.

These Are The Biggest Companies with Over 30% Sales Growth

Investors traded down the company's shares following news of a top-level managerial change.

Why Moderna Stock Was Wilting on Wednesday

The company has stood pat while other businesses have been busy with M&A.

Has Moderna Made a Bear Market Blunder?

Moderna Inc on Wednesday named former PerkinElmer executive James Mock as the company's chief financial officer, effective Sept. 6.

Moderna names PerkinElmer exec as new CFO

Moderna Inc. MRNA, -4.99% said Wednesday that Chief Financial Officer David Meline will retire, effective Sept. 6. Moderna shares fell 0.6% in premarket trading.

Moderna CFO David Meline to retire, to be succeed by PerkinElmer's James Mock

PerkinElmer

CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel.

James Mock Joins Moderna as Chief Financial Officer

There wasn't any negative news from the vaccine maker.

Why Moderna Stock Is Sliding Today

SAN MATEO, Calif.--(BUSINESS WIRE)--Moderna recently conducted a digitally enabled, at-home study examining COVID-19 antibody response over time, made possible by Evidation. A preprint published on MedRxiv, Antibody Response Following COVID-19 Boosters During the Omicron Wave in the United States: A Decentralized, Digital Health, Real-World Study, reports individuals who received Moderna primary shots and boosters had more durable antibody levels than those who received Pfizer. This observation

Evidation Enables First of Its Kind Moderna Study to Track COVID Vaccine Response in Real Life

The biotech's COVID-19 vaccine sales could be about to receive a boost.

News for Moderna Stock (MRNA)